Can this ASX healthcare stock, down 22% in a year, turn the tide after FY24 results?

How did this ASX healthcare company do in FY24?

| More on:
a concerned medical doctor examines an Xray from an imaging machine in a hospital setting.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The share price of Mach7 Technologies Ltd (ASX: M7T), a medical imaging systems provider, is down 4.2% today after the ASX healthcare company reported its FY24 results.

Mach7 Technologies shares have not performed well over the past year, falling more than 22%.

Created with Highcharts 11.4.3Mach7 Technologies PriceZoom1M3M6MYTD1Y5Y10YALL29 Aug 202328 Aug 2024Zoom ▾Sep '23Nov '23Jan '24Mar '24May '24Jul '24Oct '23Oct '23Jan '24Jan '24Apr '24Apr '24Jul '24Jul '24www.fool.com.au

Can this ASX small-cap company turn the tide here and have a chance to become the next Pro Medicus Limited (ASX: PME)?

Let's find out what the company reported for FY24.

Transition to subscription-based business continues

Key highlights from Mach7's FY24 results include:

  • Sales orders increased by 52% year-on-year to $61.3 million in terms of total contract value.
  • Revenue fell 3% to $21.1 million due to ongoing transition to recurring revenue.
  • Annual recurring revenue (ARR) was up 29% to $21.1 million and represented 72% of the total revenue, up from 54% in FY23.
  • Operating expenses increased by 13%, in line with management guidance.
  • Adjusted earnings before interests, taxes, depreciation, and amortisation (EBITDA) fell from $2.5 million in FY23 to a loss of $2 million in FY24.
  • Net profit after tax (NPAT) deteriorated to a loss of $8 million, compared to a $1 million loss in FY23.
  • Operating cashflow turned positive to $3.5 million, in line with management guidance.

What else happened in FY24?

Mach7 continues to move towards subscription-based models, particularly in North America.

Subscription and maintenance contracts now dominate Mach7's sales orders, comprising 83% of the total, and representing a substantial increase from previous years. This transition is underscored by a decline in capital software sales, which have decreased significantly in favour of subscription models.

Renewals accounted for $37.5 million or 61% of total sales, a record high for the company, while new customers, including significant projects like the Veterans Health Administration, contributed $13.2 million or 22%.

A slight decrease in overall revenue in FY24 was primarily due to the short-term impact of the subscription transition. Recurring revenue now represents 72% of total revenue, underpinned by steady growth in ARR. This trend highlights Mach7's resilience and the stability provided by its subscription-based business model.

However, weak revenue led to weaker profits for the past financial year, reflecting the anticipated short-term financial impacts of their strategic transition.

On a positive note, the company achieved a positive operating cash flow of $3.5 million, demonstrating robust cash management and financial discipline amidst its growth initiatives.

FY25 guidance

Looking ahead, the company has a strong sales pipeline across different regions, care settings and product combinations.

The company guided for 15% to 25% revenue growth in FY25. Management expects the company's operating expenses to grow slower than revenue growth, leading to margin expansion.

Mach7 CEO Mike Lampron said:

Looking ahead to FY25, our priorities will centre around the addition of net new logos as our pipeline continues to grow and generate opportunities across multiple geographies and product combinations.

We will also undertake targeted investment in our people, processes and tools to further differentiate Mach7 from its competitors. This investment will focus on product innovation and reflect a customer-centric mindset.

Share price snapshot

Mach7 shares are down 4.54% to 56.5 cents at the time of writing.

Motley Fool contributor Kate Lee has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Mach7 Technologies and Pro Medicus. The Motley Fool Australia has recommended Mach7 Technologies and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Consumer Staples & Discretionary Shares

Guess which ASX 200 stock is rocketing 26% on better than expected results

The KFC operator has delivered on expectations with its FY 2025 results.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Earnings Results

Which ASX 200 stock is up 5% to a 52-week high on results day?

This blue chip is having a strong start to the week. Let's find out why.

Read more »

A woman looks up at a plane flying in the sky with arms outstretched as the Flight Centre share price surges
Earnings Results

Web Travel share price rockets 13% on market leading full-year growth

Investors are sending Web Travel shares soaring today. Here’s why.

Read more »

Happy shopper at a clothes shop.
Earnings Results

Why did Myer shares just rocket 9%?

Investors are piling into Myer shares on Friday. But why?

Read more »

A woman looks up at a plane flying in the sky with arms outstretched as the Flight Centre share price surges
Earnings Results

Up 78% since April, why is the Webjet share price taking off again today?

Webjet shares have soared 78% since 4 April and are lifting off again today. But why?

Read more »

a woman holds her hands to her temples as she sits in front of a computer screen with a concerned look on her face.
Industrials Shares

Guess which ASX 200 stock is crashing 24% on results day

Investors were not impressed with this result. But why?

Read more »

A man in full American NFL playing kit crouches over with his arms across his chest in a defensive stance against a dark background.
Technology Shares

ASX 300 tech stock charges 7% higher to record high on stellar results

This tech stock delivered another impressive result this morning.

Read more »

a group of people sit around a computer in an office environment.
Earnings Results

Guess which ASX 200 tech stock is rocketing 12% on record results

Another half, another record result from this high-quality company.

Read more »